Fulcrum Therapeutics Inc [FULC] stock is trading at $8.84, up 4.00%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FULC shares have gain 19.62% over the last week, with a monthly amount glided 33.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Fulcrum Therapeutics Inc [NASDAQ: FULC] stock has seen the most recent analyst activity on July 29, 2025, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $12 from $4. Previously, Leerink Partners upgraded its rating to Outperform on May 23, 2025, and kept the price target unchanged to $12. On May 15, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $10 on the stock. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $4 on September 13, 2024. Stifel downgraded its rating to a Hold. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on September 12, 2024, and downed its price target to $4. In a note dated September 12, 2024, Leerink Partners downgraded an Market Perform rating on this stock but restated the target price of $4.
Fulcrum Therapeutics Inc [FULC] stock has fluctuated between $2.32 and $8.52 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $8.84 at the most recent close of the market. An investor can expect a potential return of 24.43% based on the average FULC price forecast.
Analyzing the FULC fundamentals
Fulcrum Therapeutics Inc [NASDAQ:FULC] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.31 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.53 points at the first support level, and at 8.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.06, and for the 2nd resistance point, it is at 9.27.
Ratios To Look Out For
For context, Fulcrum Therapeutics Inc’s Current Ratio is 24.42. Also, the Quick Ratio is 24.42, while the Cash Ratio stands at 4.74.
Transactions by insiders
Recent insider trading involved Tourangeau Greg, Principal Accounting Officer, that happened on May 08 ’25 when 498.0 shares were sold.
